Literature DB >> 28495524

Granulomatosis with polyangiitis (Wegener granulomatosis): A proteinase-3 driven disease?

Véronique Witko-Sarsat1, Nathalie Thieblemont2.   

Abstract

Granulomatosis with polyangiitis (GPA, Wegener granulomatosis) is a systemic autoimmune vasculitis that affects small arteries, arterioles, and capillaries, most notably in the kidneys and lungs. In this disease, proteinase-3 (PR3), produced by neutrophils, is targeted by antineutrophil cytoplasmic antibodies (ANCA). Recent work by our group has shown how PR3 impairs the resolution of inflammation and deregulates the immune system. Normally, the clearance of activated neutrophils triggers an anti-inflammatory, pro-resolution process. In patients with GPA, however, macrophages phagocytose apoptotic neutrophils then release massive amounts of pro-inflammatory mediators, notably interleukin-1, thereby generating a pro-inflammatory microenvironment conducive to autoimmunity. This deregulation of immune processes is accompanied with activation of plasmacytoid dendritic cells and with polarization of T-helper-2 (Th2), Th9, and Th17 cells. These recent data highlight the dual role of PR3, both auto-antigenic and auto-inflammatory, thus potentially opening up new therapeutic avenues.
Copyright © 2017 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Apoptosis; Autoimmunity; Inflammation; Neutrophil; Proteinase-3

Mesh:

Substances:

Year:  2017        PMID: 28495524     DOI: 10.1016/j.jbspin.2017.05.004

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  2 in total

Review 1.  Epidemiology and genetics of granulomatosis with polyangiitis.

Authors:  Pratibha Banerjee; Arushi Jain; Uma Kumar; Sabyasachi Senapati
Journal:  Rheumatol Int       Date:  2021-10-11       Impact factor: 2.631

2.  Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab.

Authors:  Shun Yoshida; Shunichiro Hanai; Daiki Nakagomi; Kei Kobayashi; Kazuya Takahashi; Fumihiko Furuya
Journal:  Intern Med       Date:  2020-08-22       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.